ES2184408T3 - Sistema transdermico que contiene un antioxidante. - Google Patents

Sistema transdermico que contiene un antioxidante.

Info

Publication number
ES2184408T3
ES2184408T3 ES99902525T ES99902525T ES2184408T3 ES 2184408 T3 ES2184408 T3 ES 2184408T3 ES 99902525 T ES99902525 T ES 99902525T ES 99902525 T ES99902525 T ES 99902525T ES 2184408 T3 ES2184408 T3 ES 2184408T3
Authority
ES
Spain
Prior art keywords
antioxidant
system containing
transdermal system
ethyl
carbamate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99902525T
Other languages
English (en)
Inventor
Bodo Asmussen
Michael Horstmann
Kai Kopke
Harry Tiemessen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
LTS Lohmann Therapie Systeme AG
Original Assignee
Novartis AG
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10825116&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2184408(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG, LTS Lohmann Therapie Systeme AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2184408T3 publication Critical patent/ES2184408T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dental Preparations (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Una composición farmacéutica que comprende (S)-N- etil-3-[(1-dimetilamino)etil]-N-metil-fenil-carbamato (Compuesto A) en forma de base libre o de sal de adición de ácido y un antioxidante.
ES99902525T 1998-01-12 1999-01-08 Sistema transdermico que contiene un antioxidante. Expired - Lifetime ES2184408T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9800526.7A GB9800526D0 (en) 1998-01-12 1998-01-12 Organic compounds

Publications (1)

Publication Number Publication Date
ES2184408T3 true ES2184408T3 (es) 2003-04-01

Family

ID=10825116

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99902525T Expired - Lifetime ES2184408T3 (es) 1998-01-12 1999-01-08 Sistema transdermico que contiene un antioxidante.

Country Status (25)

Country Link
US (1) US6335031B1 (es)
EP (1) EP1047409B1 (es)
KR (1) KR100569051B1 (es)
CN (1) CN1129427C (es)
AT (1) ATE223711T1 (es)
AU (1) AU745661B2 (es)
BR (1) BR9906920A (es)
CA (1) CA2315784C (es)
CZ (1) CZ300598B6 (es)
DE (1) DE69902875T2 (es)
DK (1) DK1047409T3 (es)
ES (1) ES2184408T3 (es)
GB (1) GB9800526D0 (es)
HU (1) HU227159B1 (es)
ID (1) ID27503A (es)
IL (1) IL137100A (es)
MX (1) MXPA00006438A (es)
NO (1) NO328390B1 (es)
NZ (1) NZ505650A (es)
PL (1) PL201328B1 (es)
PT (1) PT1047409E (es)
RU (1) RU2219926C2 (es)
SK (1) SK284622B6 (es)
TR (2) TR200001688T2 (es)
WO (1) WO1999034782A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100603900B1 (ko) 1998-10-01 2006-07-25 노파르티스 아게 신규의 서방성 경구 제제
FR2793689B1 (fr) * 1999-05-19 2001-08-24 Pf Medicament Dispositif transdermique pour l'administration de testosterone ou d'un de ses derives
PL198323B1 (pl) * 1999-11-29 2008-06-30 Lohmann Therapie Syst Lts Transdermalny system terapeutyczny zawierający wrażliwe na utlenianie substancje czynne i sposób jego wytwarzania
DE10107663B4 (de) * 2001-02-19 2004-09-09 Lts Lohmann Therapie-Systeme Ag Testosteronhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
ITMI20020798A1 (it) * 2002-04-15 2003-10-15 F T Holding S A Cerotti transdermici a matrice adesiva siliconica stabilizzati con copolimeri metacrilici
FR2881653A1 (fr) * 2005-02-04 2006-08-11 Frederic Khodja Dispositif permettant l'administration en continu d'une dose physiologique controlee d'au moins un mineral ou une vitamine
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
WO2009022345A1 (en) * 2007-08-14 2009-02-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Phenyl carbamates for the treatment of multiple sclerosis
PE20141585A1 (es) 2008-07-28 2014-11-13 Takeda Pharmaceutical Composicion farmaceutica estabilizada a base de un compuesto no petidico
US20100087768A1 (en) * 2008-10-02 2010-04-08 Forlano Paula Transdermal drug delivery system for liquid active ingredient
US10076502B2 (en) 2009-12-22 2018-09-18 Luye Pharma Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
PL2515886T3 (pl) 2009-12-22 2018-08-31 Luye Pharma Ag Przezskórny układ terapeutyczny do podawania rywastygminy lub jej pochodnych
ES2363395B1 (es) * 2010-01-20 2012-02-23 Farmalider, S.A. Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
DE102010026903A1 (de) 2010-07-12 2012-01-12 Amw Gmbh Transdermales therapeutisches System mit Avocadoöl oder Palmöl als Hilfsstoff
SG10201505658RA (en) 2010-07-21 2015-09-29 3M Innovative Properties Co Transdermal adhesive compositions, devices, and methods
SI2468274T1 (sl) 2010-12-14 2015-10-30 Acino Ag Transdermalni terapevtski sistem za dajanje aktivne snovi
KR101788802B1 (ko) * 2010-12-24 2017-10-20 주식회사 삼양바이오팜 리바스티그민을 함유하는 경피흡수제제
KR20120126898A (ko) * 2011-05-13 2012-11-21 에스케이케미칼주식회사 리바스티그민 또는 이의 염을 함유하는 경피 투여 조성물
WO2012161489A2 (ko) 2011-05-20 2012-11-29 에스케이케미칼 주식회사 리바스티그민 함유 패취
KR20120130073A (ko) * 2011-05-20 2012-11-28 에스케이케미칼주식회사 리바스티그민 함유 패취
EP2594261A1 (en) 2011-11-18 2013-05-22 Labtec GmbH Composition for transdermal administration of rivastigmine
DE102012000369A1 (de) 2012-01-11 2013-07-11 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System mit Cholinesterase-Hemmer
WO2013142339A1 (en) 2012-03-23 2013-09-26 Novartis Ag Transdermal therapeutic system and method
PL2859892T3 (pl) 2012-06-12 2023-10-16 KM Transderm Ltd. Plaster
CA2883930A1 (en) * 2012-09-03 2014-03-06 Nipro Patch Co., Ltd. Adhesive skin patch
KR20140038237A (ko) 2012-09-20 2014-03-28 에스케이케미칼주식회사 리바스티그민의 안정성이 개선된 의약품
WO2014051128A1 (ja) 2012-09-28 2014-04-03 株式会社 ケイ・エム トランスダーム 貼付剤
WO2014111790A2 (en) 2013-01-15 2014-07-24 Zydus Technologies Limited Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
CN106413695B (zh) * 2014-04-08 2019-12-10 帝国制药美国公司 利伐斯的明透皮组合物及其使用方法
JPWO2015174502A1 (ja) 2014-05-15 2017-05-25 ニチバン株式会社 リバスチグミンを含有する貼付剤のための包装体
KR102710072B1 (ko) 2018-08-31 2024-09-24 에스케이케미칼 주식회사 장기 투여용 리바스티그민 패취
KR102823139B1 (ko) 2018-08-31 2025-06-19 에스케이케미칼 주식회사 장기 투여용 리바스티그민 패취
TW202140017A (zh) * 2020-02-19 2021-11-01 日商大日本住友製藥股份有限公司 經皮吸收製劑

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
GB9213322D0 (en) * 1992-06-23 1992-08-05 Efamol Holdings Antioxidant compositions
AU5716898A (en) * 1997-01-08 1998-08-03 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
DE69802498T2 (de) * 1997-01-17 2002-07-04 Takeda Chemical Industries, Ltd. Idebenon enthaltendes kombinationspräparat zur alzheimer behandlung

Also Published As

Publication number Publication date
TR200101021T2 (tr) 2002-06-21
US6335031B1 (en) 2002-01-01
DK1047409T3 (da) 2002-12-30
HUP0004300A2 (hu) 2001-05-28
ID27503A (id) 2001-04-12
CN1288375A (zh) 2001-03-21
NO20003472L (no) 2000-08-07
NZ505650A (en) 2002-10-25
MXPA00006438A (es) 2003-07-21
GB9800526D0 (en) 1998-03-11
CA2315784C (en) 2006-06-27
JP2002500178A (ja) 2002-01-08
CZ300598B6 (cs) 2009-06-24
NO20003472D0 (no) 2000-07-05
RU2219926C2 (ru) 2003-12-27
KR100569051B1 (ko) 2006-04-10
SK10532000A3 (sk) 2000-11-07
SK284622B6 (sk) 2005-08-04
CA2315784A1 (en) 1999-07-15
WO1999034782A1 (en) 1999-07-15
EP1047409B1 (en) 2002-09-11
CZ20002557A3 (cs) 2000-10-11
PL341347A1 (en) 2001-04-09
HK1034036A1 (en) 2001-10-12
KR20010033072A (ko) 2001-04-25
PL201328B1 (pl) 2009-03-31
ATE223711T1 (de) 2002-09-15
DE69902875D1 (de) 2002-10-17
CN1129427C (zh) 2003-12-03
BR9906920A (pt) 2000-10-10
HU227159B1 (en) 2010-09-28
AU745661B2 (en) 2002-03-28
NO328390B1 (no) 2010-02-08
HUP0004300A3 (en) 2003-05-28
AU2278599A (en) 1999-07-26
JP3820103B2 (ja) 2006-09-13
IL137100A0 (en) 2001-06-14
EP1047409A1 (en) 2000-11-02
TR200001688T2 (tr) 2000-11-21
PT1047409E (pt) 2002-12-31
DE69902875T2 (de) 2003-05-22
IL137100A (en) 2004-12-15

Similar Documents

Publication Publication Date Title
ES2184408T3 (es) Sistema transdermico que contiene un antioxidante.
DK0925303T3 (da) Phosphinsyreamider som matrixmetalloproteaseinhibitorer
NO20002826D0 (no) Hydroksamsyrederivater som matriksmetallprotease (MMO) - inhibitorer
DK1156806T3 (da) Farmaceutisk sammensætning indeholdende protonpumpeinhibitor
FI20010683L (fi) Nateglinidiä sisältävä koostumus
ATE293970T1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
IS1940B (is) Lyfjasamsetningar sem innihalda HMG afoxunarensímlata
TR199501472A2 (tr) Matriks metaloproteaz inhibitörler.
EA199900373A2 (ru) Фармацевтические композиции
EA199900749A1 (ru) Фармацевтическая композиция
AU4710499A (en) Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use ofsuch compounds
PT1082109E (pt) Formulacao oral que compreende biguanidina e um acido organico
MX9800408A (es) Sales de derivados de amidina y de inhibidor de ciclooxigenasa, su procedimiento de preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
BR9806213A (pt) Forma de dosagem transdérmica.
BRPI0111911B8 (pt) preparado aplicável por via oral compreendendo ciprofloxacina
NO20030182L (no) Dermalt påföringssystem for aminolevulinsyre
EE9900180A (et) Asendatud 4-bifenüül-4-hüdroksübutaanhappe derivaadid metalloproteaasimaatriksi inhibiitoritena
MXPA03004209A (es) Composicion farmaceutica o cosmetica y uso de un inhbidor de proteina cinasa c con un inhibidor de metaloproteasas de la matriz para inhibir la migracion de celulas de langerhans.
BR0007922A (pt) Compostos calcilìticos
DK1047665T3 (da) Matrix metalloprotease inhibitorer
BR9915692A (pt) Monohidrato de bromidrato de eletriptano
AR026073A1 (es) Composicion farmaceutica acuosa que contiene ciclesonida
ID17326A (id) Turunan-turunan asam 4-arilbutirat tersubstitusi sebagai inhibitor-inhibitor matriks metalloprotease
BR0313150A (pt) Cápsulas de gelatina que exibem ligação reticulada reduzida
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent